These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7488557)

  • 21. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination antiretroviral therapy for HIV infection.
    Maenza J; Flexner C
    Am Fam Physician; 1998 Jun; 57(11):2789-98. PubMed ID: 9636341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral phenotype and genotype as markers in clinical trials.
    Katzenstein DA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S25-34. PubMed ID: 7552510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
    HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of virological response to antiretroviral therapy: implications for long-term strategies.
    Deeks SG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S177-84. PubMed ID: 10860903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review.
    Re MC; Vitone F; Bon I; Schiavone P; Gibellini D
    New Microbiol; 2006 Apr; 29(2):81-8. PubMed ID: 16841548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.
    Nowak MA; Bonhoeffer S; Shaw GM; May RM
    J Theor Biol; 1997 Jan; 184(2):203-17. PubMed ID: 9059598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery, development and characterization of agents active against the AIDS virus.
    Pauwels R; de Bethune MP; Andries K; Stoffels P; Janssen P; De Clercq E
    J Recept Signal Transduct Res; 1995; 15(1-4):609-16. PubMed ID: 8903967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV viral dynamics.
    Coffin JM
    AIDS; 1996 Dec; 10 Suppl 3():S75-84. PubMed ID: 8970715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs.
    Schooley RT
    AIDS; 1995 Dec; 9 Suppl 2():S15-S19. PubMed ID: 8775802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people.
    Onafuwa-Nuga A; McNamara LA; Collins KL
    Cell Res; 2010 Nov; 20(11):1185-7. PubMed ID: 20877313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges in the therapy of HIV infection.
    Yarchoan R; Mitsuya H; Broder S
    Immunol Today; 1993 Jun; 14(6):303-9. PubMed ID: 8397771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance, remission, and qualitative differences in HIV chemotherapy.
    Kirschner DE; Webb GF
    Emerg Infect Dis; 1997; 3(3):273-83. PubMed ID: 9284371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selection of asymptomatic HIV carriers for antiviral therapy.
    de Man RA; Schalm SW; Sprecher-Goldberger S; Stibbe J; van de Ende ME; Schrijnemakers P; Rothbarth PH
    Neth J Med; 1990 Oct; 37(3-4):141-4. PubMed ID: 2250758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory operations, specimen processing, and handling for viral load testing and surveillance.
    Puren A; Gerlach JL; Weigl BH; Kelso DM; Domingo GJ
    J Infect Dis; 2010 Apr; 201 Suppl 1():S27-36. PubMed ID: 20225943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic aspects of retroviral disease.
    Peto T
    Baillieres Clin Neurol; 1992 Apr; 1(1):239-57. PubMed ID: 1344652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV virology and pathogenetic mechanisms of infection: a brief overview.
    Fanales-Belasio E; Raimondo M; Suligoi B; Buttò S
    Ann Ist Super Sanita; 2010; 46(1):5-14. PubMed ID: 20348614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eradication of HIV--hope or hype?
    PI Perspect; 1996 Sep; (No 19):3-6. PubMed ID: 11363905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tracking episomal HIV DNA: implications for viral persistence and eradication of HIV.
    Sharkey M
    Curr Opin HIV AIDS; 2013 Mar; 8(2):93-9. PubMed ID: 23380651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.